PDCD1 and neoplasm: PD-1 blockade combined with endostar significantly suppressed tumor growth, leading to reduced IL-17 and TGF-β1 levels, increased IFN-γ secretion, decreased MDSC, and reversal of CD8+ T cell suppression.